Johnson & Johnson (JNJ) Gross Profit Growth (3y) (2012 - 2026)

Johnson & Johnson (JNJ) Gross Profit Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (3y) (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 8.42%
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 44.89%
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 3.95%
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 9.39%
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 4.61%
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 10.24%
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 3.66%
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 1.34%
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -2.75%
10 Novartis Ag 109.78 Bn 109.09 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 3.95%
Dec 28, 2025 6.20%
Sep 28, 2025 6.48%
Jun 29, 2025 5.07%
Mar 30, 2025 1.69%
Sep 29, 2024 -1.22%
Jun 30, 2024 -0.31%
Mar 31, 2024 -0.85%
Dec 31, 2023 -0.15%
Oct 1, 2023 1.48%
Jul 2, 2023 8.60%
Apr 2, 2023 1.39%
Jan 1, 2023 0.59%
Oct 2, 2022 -0.09%
Jul 3, 2022 0.66%
Apr 3, 2022 1.02%
Oct 3, 2021 5.35%
Jul 4, 2021 4.19%
Apr 4, 2021 4.44%
Jan 3, 2021 4.26%